Artwork

Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Shankar Siva on radiotherapy for primary renal cell carcinoma

8:30
 
Share
 

Manage episode 348296326 series 2829082
Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

198 episodes

Artwork
iconShare
 
Manage episode 348296326 series 2829082
Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

198 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide